The role of adjuvant therapy for pancreatic cancer

Expert Opinion on Investigational Drugs

Volumn 11, Issue 1, 2002, Pages 87-107

  Magee, C J ^a   Ghaneh, P ^a   Hartley, M ^a   Sutton, R ^a   Neoptolemos, J P ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Adjuvant therapy; Pancreatic cancer; Randomised controlled trial

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOSTATIN; BATIMASTAT; CAMPTOTHECIN; CAPECITABINE; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DNA TOPOISOMERASE INHIBITOR; DOCETAXEL; DOXORUBICIN; ENDOSTATIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; FUMAGILLOL CHLOROACETYLCARBAMATE; GASTRIN 17; GEMCITABINE; IRINOTECAN; MARIMASTAT; MATRIX METALLOPROTEINASE INHIBITOR; METHOTREXATE; MITOMYCIN C; PACLITAXEL; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RALTITREXED; RUBITECAN; UNINDEXED DRUG; VINCRISTINE;

ADVANCED CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIARRHEA; HUMAN; LIVER TOXICITY; MORBIDITY; NAUSEA; NEUTROPENIA; NONHUMAN; PANCREAS CANCER; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; SIDE EFFECT; STOMATITIS; SURGICAL MORTALITY; VOMITING;

CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS; GENE THERAPY; HUMANS; IMMUNOTHERAPY; NEOADJUVANT THERAPY; PANCREATIC NEOPLASMS; RADIOTHERAPY, ADJUVANT;

EID: 0036139695     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.11.1.87     Document Type: Review

References (159)

1. Cancer burden in the year 2000. The global picture
2. Cancer statistics, 2001
3. Cancer survival trends in England and wales, 1971-1995: Deprivation and NHS region
4. Treatment and survival in 13,560 patients with pancreatic cancer, and incidence of the disease, in the West Midlands: An epidemiological study
5. Are increasing 5-year survival rates evidence of success against cancer?
6. Molecular pathogenesis of pancreatic adenocarcinoma and clinical implications
7. Survival after pancreatoduodenectomy. 118 consecutive resections without an operative mortality
8. Resected adenocarcinoma of the pancreas-616 patients: Results, outcomes, and prognostic indicators
9. Prognostic factors for survival after pancreaticoduodenectomy for patients with carcinoma of the pancreatic head region
10. Long-term survival in pancreatic cancer: Pylorus-preserving versus Whipple pancreatoduodenectomy
11. Pancreaticoduodenectomy for pancreatic adenocarcinoma: Postoperative adjuvant chemoradiation improves survival. A prospective, single- institution experience
12. Long-term survival after resection for ductal adenocarcinoma of the pancreas. Is it really improving?
13. Prognostic indicators for survival after resection of pancreatic adenocarcinoma
14. Low mortality following resection for pancreatic and periampullary tumours in 1026 patients: UK survey of specialist pancreatic units
15. Practical usefulness of lymphatic and connective tissue clearance for the carcinoma of the pancreas head
16. Results of extensive surgery for pancreatic carcinoma
17. Recurrence after resection for ductal adenocarcinoma of the pancreas
18. Pancreatic invasion as the prognostic indicator of duodenal adenocarcinoma treated by pancreatoduodenectomy plus extended lymphadenectomy
19. The role of extended radical operation for pancreatic cancer
20. Standard versus extended lymphadenectomy associated with pancreatoduodenectomy in the surgical treatment of adenocarcinoma of the head of the pancreas: A multicenter, prospective, randomized study
21. Pancreaticoduodenectomy with or without extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma: Comparison of morbidity and mortality and short-term outcome
22. Surgical curability and prognosis for standard versus extended resection for T1 carcinoma of the pancreas
23. Prognostic factors associated with resectable adenocarcinoma of the head of the pancreas
24. Resection margins in carcinoma of the head of the pancreas. Implications for radiation therapy
25. Prognostic factors after surgical resection for pancreatic carcinoma
26. 1, erbB-2 and erbB-3 in resected pancreatic ductal adenocarcinoma
27. Moderate activation of the apoptosis inhibitor bcl-xL worsens the prognosis in pancreatic cancer
28. Patterns of failure after curative resection of pancreatic carcinoma
29. The time of occurrence of liver metastasis in carcinoma of the pancreas
30. A surgical and pathological based classification of resective treatment of pancreatic cancer. Summary of an international workshop on surgical procedures in pancreatic cancer
31. Standard Kausch-Whipple pancreatoduodenectomy
32. Randomized prospective trial of pylorus-preserving vs. Classic duodenopancreatectomy (Whipple procedure): Initial clinical results
33. Results of total pancreatectomy for adenocarcinoma of the pancreas
34. New guidelines to evaluate the response to treatment in solid tumors
35. Decrease of CA 19-9 during chemotherapy with gemcitabine predicts survival time in patients with advanced pancreatic cancer
36. CA19-9: A pedictor of response in pancreatic cancer treated with gemcitabine and cisplatin
37. Locoregional/systemic chemotherapy of locally advanced/ metastasized pancreatic cancer with a combination of mitomycin-C and gemcitabine and simultaneous follow-up by imaging methods and tumor markers
38. In vitro concentration response studies and in vitro Phase II tests as the experimental basis for regional chemotherapeutic protocols
39. Review article: Current treatment and optimal patient management in pancreatic cancer
40. Lack of efficacy of high-dose leucovorin and fluorouracil in patients with advanced pancreatic adenocarcinoma
41. Phase II trials of 5-fluorouracil and leucovorin in patients with metastatic gastric or pancreatic carcinoma
42. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer
43. Protracted venous infusion 5-fluorouracil woth or without mitomycin C in advanced pancreatic cancer
44. A Phase 2 trial of Xeloda (Capecitabine) in advanced or metastatic pancreatic cancer
45. A Phase I study of capecitabine and weekily paclitaxel in advanced solid tumours
46. Evaluation of the antitumor activity of gemcitabine (2′,2′-difluoro-2′-deoxycytidine)
47. Radiosensitization of pancreatic cancer cells by 2′,2-difluoro-2′-deoxycytidine
48. Chemotherapy in pancreatic cancer: Results of a controlled, prospective, randomised, multicentre trial
49. Randomized study of 5-FU and CCNU in pancreatic cancer
50. Chemotherapy prolongs survival in inoperable pancreatic carcinoma
51. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer
52. A Phase III trial on the therapy of advanced pancreatic carcinoma. Evaluations of the Mallinson regimen and combined 5-fluorouracil, doxorubicin, and cisplatin
53. A systematic overview of chemotherapy effects in pancreatic cancer
54. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial
55. Severe non-haematological toxicity after treatment with gemcitabine
56. Multicentre Phase II study in advanced pancreatic adenocarcinoma patients treated with a combination of leucovorin, 5-FU bolus and infusion and gemcitabine (FOLFUGEM regimen)
57. A Phase II trial of gemcitabine in combination with 5-fluorouracil (24-hour) and folinic acid in patients with chemonaive advanced pancreatic cancer
58. Eastern Cooperative Oncology Group Phase I trial of protracted venous infusion fluorouracil plus weekly gemcitabine with concurrent radiation unexpected early toxicity
59. Gemcitabine alone or with cis-platin in advanced pancreatic cancer: Prelininary results of a randomised study of the Southern Italy Oncology Group
60. Phase II study of gemcitabine and cisplatin in the treatment of patients with advanced pancreatic carcinoma
61. Intraoperative and external beam irradiation +/- 5-FU for locally advanced pancreatic cancer
62. Radiation therapy for pancreatic cancer: A retrospective study of the University of Louisville experience
63. Prognostic factors in patients with locally advanced pancreatic carcinoma receiving chemoradiotherapy
64. Paclitaxel and concurrent radiation for locally advanced pancreatic cancer
65. Feasibility and efficacy of high dose conformal radiotherapy for patients with locally advanced pancreatic carcinoma
66. High-dose preoperative external beam and intraoperative irradiation for locally advanced pancreatic cancer
67. Intraoperative radiation therapy of pancreatic cancer
68. Therapy of locally unresectable pancreatic carcinoma: A randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil
69. Combined modality treatment with accelerated radiotherapy and chemotherapy in patients with locally advanced inoperable carcinoma of the pancreas: Results of a feasibility study
70. A randomised trial of intraoperative radiation therapy (IORT) vs. IORT plus chemotherapy (MTX-5FU) for adenocarcinoma of the pancreas
71. Gemcitabine following radiotherapy with concurrent 5-fluorouracil for nonmetastatic adenocarcinoma of the pancreas
72. Combined radiochemotherapy of locally advanced unresectable pancreatic adenocarcinoma with mitomycin C plus 24-hour continuous infusional gemcitabine
73. Intra-arterial chemotherapy with MMC, CDDP and 5-FU for non-resectable pancreatic cancer-A Phase II study
74. Regional chemotherapy for inoperable pancreatic carcinoma
75. Regional versus systemic chemotherapy for advanced pancreatic cancer: A randomized study
76. Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic mice
77. Suppression of human pancreatic cancer growth in BALB/c nude mice by manumycin, a farnesyl: Protein transferase inhibitor
78. K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors
79. Irinotecan/gemcitabine combination chemotherapy in pancreatic cancer
80. A Phase II study of Rubitecan (RFS 2000, 9NC, 9-Nitro-20(S)-Camptothecin) in Patients with Refractory Pancreatic Cancer
81. The hallmarks of cancer
82. Expression of collagenase (MMP2), stromelysin (MMP3) and tissue inhibitor of the metalloproteinases (TIMP1) in pancreatic and ampullary disease
83. Imbalance of expression of matrix metalloproteinases (MMPs) and tissue inhibitors of the matrix metalloproteinases (TIMPs) in human pancreatic carcinoma
84. The matrix metalloproteinases and their inhibitors in the treatment of pancreatic cancer
85. A Phase II trial of marimastat in advanced pancreatic cancer
86. Marimastat as first-line therapy for patients with unresectable pancreatic cancer: A randomized trial
87. Effect of gastrointestinal hormones and synthetic analogues on the growth of pancreatic cancer
88. Gastrimmune raises antibodies that neutralize amidated and glycine-extended gastrin-17 and inhibit the growth of colon cancer
89. Pre-clinical evaluation of the Gastrimmune immunogen alone and in combination with 5-fluorouracil/leucovorin in a rat colorectal cancer model
90. G17DT Therapy May Improve Survival of Patients with Advanced Pancreatic Carcinoma
91. Hypoxia-inducible factor 1: Master regulator of O2 homeostasis
92. Angiogenesis inhibitor TNP-470 reduces human pancreatic cancer growth
93. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice
94. Current role of thalidomide in cancer treatment
95. Phase I trials of uracil-tegafur (UFT) using 5 and 28 day administration schedules: Demonstration of schedule-dependent toxicities
96. A Phase II study: Docetaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma
97. Combination gemcitabine and docetaxel therapy in advanced adenocarcinoma of the pancreas
98. A Phase I-II study of gemcitabine and docetaxel in advanced pancreatic cancer: A report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD)
99. Treatment of pancreatic cancer with a combination of docetaxel, gemcitabine and granulocyte colony-stimulating factor: A Phase II study of the Greek Cooperative Group for Pancreatic Cancer
100. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
101. Herceptin and Gemcitabine for Metastatic Pancreatic Cancers that Overexpress Her-2/neu
102. Intradermal ras peptide vaccination with granulocyte-macrophage colony-stimulating factor as adjuvant: Clinical and immunological responses in patients with pancreatic adenocarcinoma
103. Cytokine-mediated enhancement of epidermal growth factor receptor expression provides an immunological approach to the therapy of pancreatic cancer
104. Resistance of pancreatic carcinoma cells is reversed by co-culturing NK-like T cells with dendritic cells pulsed with tumor-derived RNA and CA 19-9
105. Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: A phase i trial of safety and immune activation
106. A Phase I clinical trial of lethally irradiated allogeneic pancreatic tumor cells transfected with the GM-CSF gene for the treatment of pancreatic adenocarcinoma
107. Pilot trial of vaccination with autologous tumor-derived gp96 Heat Shock protein peptide Complex (HSPPC-96) in patients with resected pancreatic adenocarcinoma
108. Growth inhibition of human pancreatic cancer cell lines by anti-sense oligonucleotides specific to mutated K-ras genes
109. The cancer-associated Sm-like oncogene: A novel target for the gene therapy of pancreatic cancer
110. Adenovirus-mediated wild-type p53 tumor suppressor gene therapy induces apoptosis and suppresses growth of human pancreatic cancer
111. Adenovirus-mediated transfer of p53 and p16(INK4a) results in pancreatic cancer regression in vitro and in vivo
112. P16INK4a expression adenovirus vector to suppress pancreas cancer cell proliferation
113. Intraperitoneal delivery of hrR3 and ganciclovir prolongs survival in mice with disseminated pancreatic cancer
114. Enhanced pancreatic tumor regression by a combination of adenovirus and retrovirus-mediated delivery of the herpes simplex virus thymidine kinase gene
115. Targeted killing of carcinoembryonic antigen (CEA)-producing cholangiocarcinoma cells by polyamidoamine dendrimer-mediated transfer of an Epstein-Barr virus (EBV)-based plasmid vector carrying the CEA promoter
116. Hepatic intra-arterial delivery of a retroviral vector expressing the cytosine deaminase gene, controlled by the CEA promoter and intraperitoneal treatment with 5-fluorocytosine suppresses growth of colorectal liver metastases
117. Virus directed enzyme prodrug therapy for ovarian and pancreatic cancer using retrovirally delivered E. coli nitroreductase and CB1954
118. Sensitization of colorectal and pancreatic cancer cell lines to the prodrug 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954) by retroviral transduction and expression of the E. coli nitroreductase gene
119. Microencapsulated cell-mediated treatment of inoperable pancreatic carcinoma
120. Effective gene therapy for pancreatic cancer by cytokines mediated by restricted replication-competent adenovirus
121. A Phase I/II trial of intratumoral endoscopic ultrasound (EUS) injection of Onyx-015 with intravenous gemcitabine in unresectable pancreatic carcinoma
122. Is the long-term survival rate improved by preoperative irradiation prior to Whipple's procedure for adenocarcinoma of the pancreatic head?
123. Preoperative chemoradiation for adenocarcinoma of the pancreas and duodenum
124. Preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for adenocarcinoma of the pancreatic head
125. Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas
126. Phase II trial of preoperative radiation therapy and chemotherapy for patients with localized, resectable adenocarcinoma of the pancreas: An Eastern Cooperative Oncology Group Study
127. Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: Treatment variables and survival duration
128. Preoperative chemoradiation for marginally resectable adenocarcinoma of the pancreas
129. Survival advantage of combined chemoradiotherapy compared with resection as the initial treatment of patients with regional pancreatic carcinoma. An outcomes trial
130. Preoperative chemotherapy, radiotherapy, and surgical resection of locally advanced pancreatic cancer
131. Preoperative chemoradiation for patients with locally advanced adenocarcinoma of the pancreas
132. Neoadjuvant radio-chemotherapy in advanced primarily non-resectable carcinomas of the pancreas
133. Rapid-fractionation preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for resectable pancreatic adenocarcinoma
134. Adjuvant combination chemotherapy (AMF) following radical resection of carcinoma of the pancreas and papilla of Vater-results of a controlled, prospective, randomised multicentre study
135. Results of resection for cancer of the exocrine pancreas: A study from the French Association of Surgery
136. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: A randomised controlled study
137. Patterns of disease recurrence following definitive therapy of adenocarcinoma of the pancreas using surgery and adjuvant radiotherapy: Correlations of a clinical trial
138. Intraoperative and postoperative radiotherapy in pancreatic cancer
139. Pancreatic resection combined with intraoperative radiation therapy for pancreatic cancer
140. Results of surgery and adjuvant radiotherapy for pancreatic cancer
141. Outcome of pancreaticoduodenectomy and impact of adjuvant therapy for ampullary carcinomas
142. Improved survival and local control after intraoperative radiation therapy and postoperative radiotherapy: A multivariate analysis of 46 patients undergoing surgery for pancreatic head cancer
143. Intraoperative radiation therapy adjuvant to resection in the treatment of pancreatic cancer
144. Adjuvant radiation therapy for pancreatic cancer: A 15-year experience
145. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: Phase III trial of the EORTC gastrointestinal tract cancer cooperative group
146. Adjuvant radiotherapy and concomitant 5-fluorouracil by protracted venous infusion for resected pancreatic cancer
147. Long-term survival after multimodality treatment for resectable pancreatic cancer
148. Regional celiac artery infusion as adjuvant treatment after pancreatic cancer resection
149. Regional treatment of advanced nonresectable and of resected pancreatic cancer via celiac axis infusion. First results of a single instituion study
150. Intraarterial adjuvant chemotherapy after pancreaticoduodenectomy for pancreatic cancer: Significant reduction in occurrence of liver metastasis
151. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection
152. Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer
153. Long-term survival after curative resection for pancreatic ductal adenocarcinoma. Clinicopathologic analysis of 5-year survivors
154. Adjuvant radiotherapy and follow-on chemotherapy in patients with pancreatic cancer: Results of the UK Pancreatic Cancer study (UKPACA-1)
155. Intensified adjuvant therapy for pancreatic and periampullary adenocarcinoma: Survival results and observations regarding patterns of failure, radiotherapy dose and CA19-9 levels
156. Resected pancreatic cancer treated with adjuvant radiotherapy with or without 5-fluorouracil: Treatment results and patterns of failure
157. Combined radiotherapy and chemotherapy (cisplatin and 5-fluorouracil) as palliative treatment for localized unresectable or adjuvant treatment for resected pancreatic adenocarcinoma: Results of a feasibility study
158. Interferon-based adjuvant chemoradiation therapy improves survival after pancreaticoduodenectomy for pancreatic adenocarcinoma
159. Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer